Join the Dr
Sumbul Khalid and Her speaker session.
Do
we need pharmacovigilance of drugs like metformin?
Diabetes
Mellitus is an overwhelming medical crisis for Pakistan (ranked 6th
globally) with an expected 14.5 million patients by 2025. Type 2 Diabetes
Mellitus (T2DM) predominates, with around 90%, of all the reported diabetic
cases in Pakistan. Metformin (Glucophage) is the go-to, first-line
In this era of personalized medication, it has
been established that genetic factors are responsible for 64% to 94% of
variations in an individual for renal clearance of any specific drug, including
metformin.
They
conducted a study to estimate the contribution of genotypic differences among
diabetics for their individual Responses to metformin affects. Many SNPs from
the genes associated with metformin pharmacokinetics were found associated with
these differences. The analyzed genes were SLC22A1,
SLC22A2, SLC22A3, SLC47A1 and SLC47A2. We report strong, statistically significant, associations
of certain SNPs with the ineffectiveness of metformin in non-responding patients.
Assessment
of individual responses (or no responses) of patients to their prescribed drugs
come under the umbrella of 'Pharmacovigilance' and
it is recommended that medical practitioners all over the world, but
particularly in Pakistan, may consider the genotypic evaluation of their patients
before prescribing metformin to all the patients, since a good (35%) patients
do not respond to metformin.
So,
what might be the better medication?
Conference
Name: 2nd International Conference on Clinical Trials &
Pharmacovigilance
Have
your own answers, submit your speech here
Whatsapp:
44 14 03 5820 77
Twitter:
@clinical_events
No comments:
Post a Comment